El-Rayes B - Search Results

1

CheckMate 040 cohort 5: A phase I/II study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis.

Kudo M, Matilla A, Santoro A, Melero I, Gracián AC, Acosta-Rivera M, Choo SP, El-Khoueiry AB, Kuromatsu R, El-Rayes B, Numata K, Itoh Y, Di Costanzo F, Crysler O, Reig M, Shen Y, Neely J, Tschaika M, Wisniewski T, Sangro B. Kudo M, et al. J Hepatol. 2021 Sep;75(3):600-609. doi: 10.1016/j.jhep.2021.04.047. Epub 2021 May 26. J Hepatol. 2021. PMID: 34051329 Free article.

2

Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.

Prajapati HJ, Dhanasekaran R, El-Rayes BF, Kauh JS, Maithel SK, Chen Z, Kim HS. Prajapati HJ, et al. J Vasc Interv Radiol. 2013 Mar;24(3):307-15. doi: 10.1016/j.jvir.2012.11.026. Epub 2013 Jan 29. J Vasc Interv Radiol. 2013. PMID: 23375519

3

Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.

Xing M, Webber G, Prajapati HJ, Chen Z, El-Rayes B, Spivey JR, Pillai AA, Kim HS. Xing M, et al. J Gastroenterol Hepatol. 2015 Jul;30(7):1167-74. doi: 10.1111/jgh.12920. J Gastroenterol Hepatol. 2015. PMID: 25675849

4

Evaluation of hepatic impairment on pharmacokinetics and safety of crizotinib in patients with advanced cancer.

El-Khoueiry AB, Sarantopoulos J, O'Bryant CL, Ciombor KK, Xu H, O'Gorman M, Chakrabarti J, Usari T, El-Rayes BF. El-Khoueiry AB, et al. Cancer Chemother Pharmacol. 2018 Apr;81(4):659-670. doi: 10.1007/s00280-018-3517-8. Epub 2018 Feb 21. Cancer Chemother Pharmacol. 2018. PMID: 29468455 Free PMC article. Clinical Trial.

5

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients With Cancer Living With HIV: A Perspective on Recent Progress and Future Needs.

Sahin IH, Kane SR, Brutcher E, Guadagno J, Smith KE, Wu C, Lesinski GB, Gunthel CJ, El-Rayes BF. Sahin IH, et al. JCO Oncol Pract. 2020 Jun;16(6):319-325. doi: 10.1200/JOP.19.00754. Epub 2020 Mar 11. JCO Oncol Pract. 2020. PMID: 32160138

6

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.

Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, Tovoli F, Knox JJ, Ruth He A, El-Rayes BF, Acosta-Rivera M, Lim HY, Neely J, Shen Y, Wisniewski T, Anderson J, Hsu C. Yau T, et al. JAMA Oncol. 2020 Nov 1;6(11):e204564. doi: 10.1001/jamaoncol.2020.4564. Epub 2020 Nov 12. JAMA Oncol. 2020. PMID: 33001135 Free PMC article. Clinical Trial.

7

Impact of Sarcopenia, BMI, and Inflammatory Biomarkers on Survival in Advanced Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody.

Akce M, Liu Y, Zakka K, Martini DJ, Draper A, Alese OB, Shaib WL, Wu C, Wedd JP, Sellers MT, Bilen MA, El-Rayes BF. Akce M, et al. Am J Clin Oncol. 2021 Feb 1;44(2):74-81. doi: 10.1097/COC.0000000000000787. Am J Clin Oncol. 2021. PMID: 33350681

8

A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers.

El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S, Almhanna K, Smith D, Philip PA. El-Rayes BF, et al. Ann Oncol. 2010 Oct;21(10):1999-2004. doi: 10.1093/annonc/mdq065. Epub 2010 Mar 23. Ann Oncol. 2010. PMID: 20332133 Free PMC article. Clinical Trial.

9

Clinically relevant biomarkers to select patients for targeted inhibitor therapy after resection of hepatocellular carcinoma.

Patel SH, Kneuertz PJ, Delgado M, Kooby DA, Staley CA 3rd, El-Rayes BF, Kauh JS, Sarmiento JM, Hanish S, Cohen C, Farris AB 3rd, Maithel SK. Patel SH, et al. Ann Surg Oncol. 2011 Nov;18(12):3384-90. doi: 10.1245/s10434-011-1775-3. Epub 2011 May 18. Ann Surg Oncol. 2011. PMID: 21590454

10

Safety and feasibility of same-day discharge of patients with unresectable hepatocellular carcinoma treated with doxorubicin drug-eluting bead transcatheter chemoembolization.

Prajapati HJ, Rafi S, El-Rayes BF, Kauh JS, Kooby DA, Kim HS. Prajapati HJ, et al. J Vasc Interv Radiol. 2012 Oct;23(10):1286-93.e1. doi: 10.1016/j.jvir.2012.07.003. J Vasc Interv Radiol. 2012. PMID: 22999748

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

287 results

Search Page